OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Does the small tyrosine kinase inhibitor imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?
Nils Welsh
Expert Opinion on Investigational Drugs (2012) Vol. 21, Iss. 11, pp. 1743-1750
Open Access | Times Cited: 9

Showing 9 citing articles:

Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Athanasios Fountas, Leonidas Nikolaos Diamantopoulos, Agathocles Tsatsoulis
Trends in Endocrinology and Metabolism (2015) Vol. 26, Iss. 11, pp. 643-656
Closed Access | Times Cited: 88

Synergistic Effects of Milk-Derived Exosomes and Galactose on α-Synuclein Pathology in Parkinson’s Disease and Type 2 Diabetes Mellitus
Bodo C. Melnik
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1059-1059
Open Access | Times Cited: 36

β‐Cell inflammation in human type 2 diabetes and the role of autophagy
Lorella Marselli, Marco Bugliani, Mara Suleiman, et al.
Diabetes Obesity and Metabolism (2013) Vol. 15, Iss. s3, pp. 130-136
Closed Access | Times Cited: 39

Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature
Dominika Labochka, Barbara Moszczuk, Wojciech Kukwa, et al.
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 6, pp. 1887-1894
Open Access | Times Cited: 37

Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes
Patrícia O. Prada, Mario JA Saad
Expert Opinion on Investigational Drugs (2013) Vol. 22, Iss. 6, pp. 751-763
Closed Access | Times Cited: 31

Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors
P. Buffier, Benjamin Bouillet, Sarra Smati, et al.
Annales d Endocrinologie (2018) Vol. 79, Iss. 5, pp. 574-582
Closed Access | Times Cited: 26

Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice
Janet Lau, Qiang Zhou, Susan Sutton, et al.
PLoS ONE (2014) Vol. 9, Iss. 1, pp. e84900-e84900
Open Access | Times Cited: 10

Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
Nils Welsh
Upsala Journal of Medical Sciences (2022) Vol. 127
Open Access | Times Cited: 1

Page 1

Scroll to top